摘要
目的:探讨经直肠超声彩色血流平均密度(TRUS-MCVD)对前列腺增生和前列腺癌的鉴别诊断价值。材料和方法:应用经直肠彩色血流能量成像(TR-CPA)检测60例前列腺增生和22例前列腺癌患者,计算前列腺病变区域单位面积的彩色血流平均密度(MCVD),并做组间对比;其中前列腺癌临床分期的MCVD做组间对比。结果:前列腺增生组MCVD为(0.0857±0.0348)小于前列腺癌组(0.2400±0.0851);前列腺癌组D期MCVD(0.3488±0.0522)显著高于A期MCVD(0.2170±0.0354)、B期MCVD(0.2231±0.0814)、C期MCVD(0.2252±0.0924)(P<0.05)。结论:TRUS-MCVD可做为前列腺增生和前列腺癌的鉴别诊断依据,并能于术前评价前列腺癌的预后。
Objective: To explore the value of transrectal ultrasound-mean color vessel density(TRUS-MCVD) in benign prostate hypertrophy(BPH) and prostate cancer(PCa). Materials and Methods: Twenty-two cases of PCa and 60 cases of BPH were examined with transrectal color power angiography(TR-CPA), MCVD of focal lesions were calculated with Auto CAD2004 software and had been compared with each other. Results of PCa were compared with their clinical stages. Results: MCVD of PCa group were significantly higher than that of the BPH group(0.2400±0.0851 vs 0.0857±0.2867, P〈0.01). There was significantly difference between stage D and stage A, B, C in PCa(0.3488±0.0522 vs 0.2170±0354, 0.2231±0814, 0.2252±0.0924, P〈0.05). Conclusion: The TRUS-MCVD can provide objective evidence for differential diagnosis of PCa and BPH, moreover, it is helpful in predicting the prognosis of PCa before treatment.
出处
《中国临床医学影像杂志》
CAS
北大核心
2006年第5期264-265,共2页
Journal of China Clinic Medical Imaging
基金
河北省卫生厅科技攻关课题(编号:03010)
关键词
前列腺增生
前列腺肿瘤
超声检查
prostatic hyperplasia
prostatic neoplasms
ultrasonography